GlassScriptPhysician profile
Nkiruka U Arene
NPI 1477517332
$2,618.72
in general payments reported to CMS, 2019-2025
32 companies · $749 in 2025
The $749 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $170 · 2022: $325 · 2023: $227 · 2024: $637 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.18 | 2022-2025 | Ubrelvy, Botox, Qulipta |
| Indivior INC. | $224.07 | 2019-2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $164.47 | 2022-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $163.08 | 2024-2025 | Intellis Adaptivestim, Synchromedii |
| Flowonix Medical Incorporated | $131.03 | 2020 | |
| Lilly USA, LLC | $121.73 | 2019-2024 | Emgality |
| Orexo US, INC. | $114.70 | 2019-2025 | Zubsolv |
| Braeburn INC. | $83.91 | 2024-2025 | Brixadi |
| Tersera Therapeutics LLC | $80.45 | 2019-2023 | Prialt |
| Lundbeck LLC | $78.25 | 2024 | Vyepti |
| Pfizer INC. | $74.95 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $54.18 | 2025 | |
| Allergan, INC. | $48.68 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.26 | 2019-2024 | Relistor |
| Kaleo, INC. | $45.47 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $42.85 | 2019 | |
| Boston Scientific Corporation | $34.88 | 2022 | |
| Revance Therapeutics, INC. | $33.94 | 2024 | Daxxify |
| Scilex Pharmaceuticals INC. | $32.73 | 2019 | |
| Daiichi Sankyo INC. | $31.64 | 2019 | |
| Tonix Medicines, INC. | $24.90 | 2025 | Tonmya |
| Novartis Pharmaceuticals Corporation | $23.32 | 2020 | |
| Amgen INC. | $22.46 | 2019 | |
| Kyowa Kirin, INC. | $22.18 | 2023 | Crysvita |
| Idorsia Pharmaceuticals US INC | $21.50 | 2024 | Quviviq |
| Valinor Pharma, LLC | $19.44 | 2025 | Movantik |
| Teva Pharmaceuticals USA, INC. | $16.35 | 2019 | |
| Dynasplint Systems INC. | $15.51 | 2019 | |
| Biodelivery Sciences International, INC. | $12.37 | 2019 | |
| Bioventus LLC | $11.72 | 2019 | |
| Mdd US Operations, LLC | $10.84 | 2019 | |
| Grt US Holding, INC. | $8.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nkiruka Arene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.